RxDoctor Payments Data

Layal Abdel Rahman, MD

Nephrology · Largo, FLNPI 1134383615

Payments from drug & device makers

$835in general payments, 2019–2025

Across 25 payments — averaging $33.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veloxis Pharmaceuticals, Inc.$209
  • Vifor Pharma, Inc.$117
  • E.r. Squibb & Sons, L.L.C.$113
  • Novartis$94
  • AbbVie$56
  • Shionogi Inc$51
  • plus $195 from 8 others

What the payments were for

  • Food & beverage$80196%
  • Entertainment$344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$835 in reported general payments places this provider in the 30th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$15,350
Medicare patients
33
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrevymisLetermovir24$174,165
Valganciclovir Hcl74$52,794
LokelmaSodium Zirconium Cyclosilicate23$37,862
Atovaquone64$33,390
Cinacalcet Hcl86$32,182
EliquisApixaban28$28,140
NulojixBelatacept12$24,284
FarxigaDapagliflozin Propanediol14$13,961
Nifedipine ErNifedipine212$8,935
Envarsus XrTacrolimus12$6,387
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,018
Leflunomide32$4,515
Mycophenolic AcidMycophenolate Sodium18$3,083
Fluconazole51$2,827
Humalog Kwikpen U-100Insulin Lispro12$2,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$17$51,82237 claims
E.r. Squibb & Sons, L.L.C.Nulojix$113$24,28412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 756 nephrology providers in Florida.

Other nephrology in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →